Market Overview
Global Enzyme Linked Immunosorbent Assay Market reached US$ 2.39 billion in 2025 and is expected to reach US$ 3.76 billion by 2033, growing at a CAGR of 5.8% during the forecast period 2026-2033.
Enzyme-linked Immunosorbent Assay is useful for detecting and estimating hormone levels such as human chorionic gonadotropin (HCG), follicle-stimulating hormone (FSH), and testosterone, as well as tracking disease outbreaks in communities such as chlamydia or influenza (the flu), and screening blood donations for possible viral components such as HIV. It detects nonmedical drug usage, such as the presence of amphetamines and cocaine in the body.
Rising infectious diseases globally are expected to drive the demand for enzyme-linked immunosorbent assay tests due to their specificity and identification of the antibodies. For instance, according to the World Health Organization's (WHO) 2024 Global Hepatitis Report, the number of deaths from viral hepatitis is rising. The disease is the second leading infectious cause of death in the world, accounting for 1.3 million deaths annually.
Market Scope
Metrics | Details |
CAGR | 5.8% |
Market Size Available for Years | 2023-2033 |
Estimation Forecast Period | 2026-2033 |
Revenue Units | Value (US$ Mn) |
Segments Covered | Test Type, Product, Application, End-user |
Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
Largest Region | North America |
Fastest Growing Region | Asia-Pacific |
Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
The enzyme-linked immunosorbent assay market is driven by the increasing demand for accurate and early disease diagnosis, particularly for infectious diseases, cancer, autoimmune disorders, and hormonal conditions. The growing burden of chronic and infectious diseases, along with rising awareness of preventive healthcare, is significantly boosting the adoption of ELISA-based diagnostic tests. Additionally, expanding applications in vaccine development, drug discovery, and biotechnology research are further supporting market growth. Continuous advancements in ELISA technologies, including automation, multiplexing, and enhanced sensitivity, are improving testing efficiency and throughput. The expansion of diagnostic laboratories, rising healthcare investments, and the growing use of ELISA in both clinical and research settings are also key factors accelerating market expansion.
However, the market faces challenges such as high costs associated with ELISA kits, reagents, and automated systems, which can limit adoption in price-sensitive regions. Stringent regulatory requirements for diagnostic approvals and quality standards may delay product launches and increase compliance burdens. Additionally, competition from alternative diagnostic technologies such as chemiluminescence immunoassays and molecular diagnostics creates market pressure. Issues related to reagent stability, lack of standardization, and the need for skilled professionals can also affect test accuracy and scalability. Despite these challenges, significant opportunities exist in the growing demand for point-of-care diagnostics, personalized medicine, and expanding healthcare infrastructure in emerging economies. Continuous innovation, increasing research investments, and integration of advanced technologies are expected to drive sustained market growth.
Recent Developments
February 2026: Across North America, Europe, and Asia Pacific, rising prevalence of infectious and chronic diseases significantly accelerated demand for Enzyme Linked Immunosorbent Assay (ELISA) solutions, widely used in diagnostics, drug development, and research applications.
January 2026: Advancements in high-throughput automated ELISA systems, multiplex assays, and AI-integrated data analysis improved testing efficiency, sensitivity, and scalability in clinical and laboratory workflows.
December 2025: Leading companies such as Thermo Fisher Scientific, Bio-Rad Laboratories, Merck KGaA, Danaher Corporation, and F. Hoffmann-La Roche Ltd expanded ELISA kits, reagents, and automated platforms to strengthen global market presence.
November 2025: Increasing adoption of ELISA in clinical diagnostics, including infectious disease testing, oncology biomarkers, and autoimmune disorder screening, significantly boosted market demand across healthcare systems.
October 2025: Growing focus on point-of-care and miniaturized ELISA systems enabled faster testing, reduced turnaround times, and expanded accessibility in resource-limited settings.
September 2025: In the United States, strong healthcare infrastructure, high diagnostic testing volumes, and advanced R&D capabilities significantly supported market growth.
August 2025: In China, India, and Japan, increasing healthcare investments, expansion of diagnostic laboratories, and rising disease burden accelerated regional market expansion.
July 2025: Continuous innovation in assay sensitivity, automation, and integration with digital laboratory systems, along with expanding applications in drug discovery and biomarker research, supported long-term global growth of the ELISA market.Market Segmentation
By Test Type
- Direct ELISA
- Indirect ELISA
- Sandwich ELISA
- Competitive ELISA
By Product
- Kits & Reagents
- ELISA Analyzers
- Automated
- Semi-automated
By Application
- Drug Discovery
- Infectious Diseases
- Cancer Detection
- Protein Quantification
- Others
By End-user
- Hospitals
- Academic and Research Institutes
- Pharmaceutical & Biotechnology Companies
- Diagnostic Laboratories
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the market include Thermo Fisher Scientific, Inc., American Laboratory Products Company (ALPCO), ZEUS Scientific, Inc., Life Technologies Corporation, Bio-Rad Laboratories, Inc., QuidelOrtho Corporation, Biomerieux S.A., Gemelli Biotech, BD and Enzo Biochem Inc. among others.
Why Purchase the Report?
- To visualize the global enzyme-linked immunosorbent assay market segmentation based on test type, product, application, end-user, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of enzyme-linked immunosorbent assay market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global enzyme-linked immunosorbent assay market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2026
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
